Department of Cardiovascular Diseases, University Hospital "Sveti Duh", Zagreb, Croatia.
University of Zagreb School of Medicine, Zagreb, Croatia.
Indian J Pharmacol. 2019 Nov-Dec;51(6):413-415. doi: 10.4103/ijp.IJP_562_18. Epub 2020 Jan 16.
We present a case report of a heart failure patient after heart transplantation due to end-stage ischemic cardiomyopathy with significant clinical and echocardiographic improvement 3 months after the introduction of sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor. This new class of drugs is proved to be beneficial in heart failure patients, especially with reduced ejection fraction (HFrEF), but they have not yet been used in heart failure patients after heart transplantation. We believe that the increase of left ventricular systolic function, improvement of global longitudinal strain, and reduction of pulmonary hypertension with consequent clinical recovery in our patient may have been caused by sacubitril/valsartan.
我们报告了一例心力衰竭患者，该患者因终末期缺血性心肌病在心脏移植后心力衰竭，在使用沙库巴曲缬沙坦（一种血管紧张素受体-脑啡肽酶抑制剂） 3 个月后，临床和超声心动图均显著改善。这种新型药物已被证明对心力衰竭患者（特别是射血分数降低的心力衰竭患者，即 HFrEF）有益，但尚未在心脏移植后心力衰竭患者中使用。我们认为，我们的患者左心室收缩功能增加、整体纵向应变改善、肺动脉高压降低，继而临床状况恢复，可能是由沙库巴曲缬沙坦引起的。
